Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 13, 2003. The report details changes in directors' interests in the company's Ordinary Shares and transactions related to employee incentive plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance and shareholding disclosures rather than financial performance.
Material Changes
The following material changes in shareholdings were reported:
- Employee Trust Transfers (August 12, 2003): Abacus (GSK) Trustees Limited transferred 4,520 Ordinary Shares on behalf of participants in the Glaxo Wellcome 1999 Long Term Incentive Plan and 3,832 Ordinary Shares on behalf of participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Share Acquisition (August 11, 2003): Director Mr. J D Coombe acquired 22 Ordinary Shares (11 via personal contribution and 11 via company matching) under the ShareReward Plan at a price of £11.936 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a notification of specific share transactions and does not contain forward-looking statements or risk assessments.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust and the impact of the reported transfers on director beneficial ownership.
- Confirm the terms of the ShareReward Plan regarding the matching contribution ratio for Director Mr. J D Coombe.
- Review the full 20-F annual report for comprehensive financial data, as this 6-K filing contains no financial metrics.